HealthCare Royalty Announces Royalty Monetization Agreement for Modeyso® Commercial Royalties [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
with the Advisory Group representing the former Oncoceutics Inc. securityholders for an undisclosed percentage of royalties on Modeyso ® (dordaviprone) commercial sales. Modeyso received U.S. FDA accelerated approval in August 2025 for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. Modeyso is commercialized by Jazz Pharmaceuticals. "Since its launch in August, Modeyso has demonstrated strong early performance, reflecting the significant unmet need, high awareness driven by advocacy groups, and the value physicians see for patients with H3 K27M-mutant diffuse midline glioma," said Clarke Futch, Chairman and Chief Executive Officer of HealthCare Royalty. "We believe Modeyso is uniquely positioned to bring meaningful benefit to patients who previously had no approved treatment options, and we are pleased to add this important therapy to HCRx's growing por
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Tuberous Sclerosis Complex Market Research and Global Long-term Forecast Report 2026-2035 Featuring Prominent Players - Novartis, Jazz Pharmaceuticals, Nobelpharma America [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals (JAZZ) had its price target raised by Leerink Partners from $215.00 to $225.00. They now have an "outperform" rating on the stock.MarketBeat
- 3 Reasons to Sell JAZZ and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026PR Newswire
- Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026PR Newswire
JAZZ
Earnings
- 2/24/26 - Beat
JAZZ
Sec Filings
- 4/3/26 - Form 4
- 4/1/26 - Form 144
- 3/27/26 - Form SCHEDULE
- JAZZ's page on the SEC website